# Gevokizumab

| | |
|---|---|
| **Cat. No.:** | HY-P99171 |
| **CAS No.:** | 1129435-60-4 |
| **Target:** | Interleukin Related |
| **Pathway:** | Immunology/Inflammation |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |

## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2]. |
| **In Vitro** | Gevokizumab (5 nM; 16 h) shows inhibitory effects of IL-1β-mediated NF-kB activation caused by the soluble receptors, sIL-1RI and sIL-1RII in HeLa cells[1].<br>Gevokizumab (1.85, 5.55, 16.66, and 50 nM) is a selective negative allosteric modulator which reduces the binding affinity of sIL-1RI to IL-1β[1].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| **In Vivo** | Gevokizumab (1 mg/kg; i.v.; once daily for 3 d) improves endothelial regrowth and reduces neointima formation in rats following carotid denudation[2].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|---|---|
| Animal Model: | Rat carotid denudation model in Sprague-Dawley rats (3-month0-old, 330-360 g)[2] |
| Dosage: | 1, 10 and 50 mg/kg |
| Administration: | Intravenous injection; once daily for 3 days |
| Result: | Decreased carotid intima-media thickness (IMT) in the proximal part of the denuded artery at day 28, and improved endothelial regrowth at 1 mg/kg. |

## REFERENCES

[1]. Issafras H, et al. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014 Jan;348(1):202-15.

[2]. Roubille F, et al. The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model. Atherosclerosis. 2014 Oct;236(2):277-85.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA